Sino Biopharmaceutical (HKSE:01177) Beginning Cash Position : HK$8,080 Mil (As of Jun. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Beginning Cash Position?

Sino Biopharmaceutical's Beginning Cash Position for the quarter that ended in Jun. 2024 was HK$8,080 Mil.

Sino Biopharmaceutical's quarterly Beginning Cash Position declined from Jun. 2023 (HK$9,466 Mil) to Dec. 2023 (HK$3,603 Mil) but then increased from Dec. 2023 (HK$3,603 Mil) to Jun. 2024 (HK$8,080 Mil).

Sino Biopharmaceutical's annual Beginning Cash Position declined from Dec. 2021 (HK$13,009 Mil) to Dec. 2022 (HK$10,720 Mil) and declined from Dec. 2022 (HK$10,720 Mil) to Dec. 2023 (HK$9,466 Mil).

Sino Biopharmaceutical Beginning Cash Position Historical Data

The historical data trend for Sino Biopharmaceutical's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Beginning Cash Position Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

6,938.03

12,602.58

13,008.98

10,719.94

9,466.44

Sino Biopharmaceutical Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Beginning Cash Position	Get a 7-Day Free Trial															11,252.56	6,773.37	9,466.46	3,602.87	8,079.57

Sino Biopharmaceutical Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Sino Biopharmaceutical Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Executives

Tse Ping	2101 Beneficial owner
Tse Eric S Y	2101 Beneficial owner
Cheng Cheung Ling	2101 Beneficial owner
True Merit Global Limited	2101 Beneficial owner
Tse Theresa Y Y	2101 Beneficial owner
Thousand Eagles Limited	2101 Beneficial owner
France Investment (china 1) Group Limited	2101 Beneficial owner
Remarkable Industries Limited	2101 Beneficial owner
Validated Profits Limited	2101 Beneficial owner

Sino Biopharmaceutical Headlines

No Headlines